[1] Chalasani N, Younossi Z, Lavine JE,et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012,55:2005-2023. [2] Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci,2013,1281:106-122. [3] Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology,2004,40:1387-1395. [4] Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol,2009,50:204-210. [5] Day CP, James OF. Steatohepatitis: a tale of two "hits" Gastroenterology, 1998,114:842-845. [6] Cooper HL, Park MH, Folk JE, et al. Identification of the hypusine- containing protein hy+ as translation initiation factor eIF-4D. Proc Natl Acad Sci U S A,1983,80:1854-1857. [7] Maier B, Ogihara T, Trace AP, et al. The unique hypusine modification of eIF5A promotes islet beta cell inflammation and dysfunction in mice. J Clin Invest,2010,120:2156-2170. [8] Pasarin M, Abraldes JG, Rodriguez-Vilarrupla A,et al. Insulin resistance and liver microcirculation in a rat model of early NAFLD. J Hepatol, 2011,55:1095-1102. [9] Shinozaki S, Choi CS, Shimizu N, et al. Liver-specific inducible nitric-oxide synthase expression is sufficient to cause hepatic insulin resistance and mild hyperglycemia in mice. J Biol Chem,2011,286:34959-34975. [10] Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005,41:1313-1321. [11] Ma X, Hua J, Mohamood AR, et al. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology, 2007,46:1519-1529. [12] Park MH, Nishimura K, Zanelli CF, et al. Functional significance of eIF5A and its hypusine modification in eukaryotes.Amino Acids,2010,38:491-500. [13] Wolff EC, Kang KR, Kim YS, et al. Posttranslational synthesis of hypusine: evolutionary progression and specificity of the hypusine modification. Amino Acids, 2007,33:341-350. [14] Pallmann N, Braig M,Sievert H,et al. Biological Relevance and Therapeutic Potential of the Hypusine Modification System. J Biol Chem,2015,290:18343-18360. [15] Kemper WM, Berry KW, Merrick WC. Purification and properties of rabbit reticulocyte protein synthesis initiation factors M2Balpha and M2Bbeta. J Biol Chem, 1976,251:5551-5557. [16] Saini P, Eyler DE, Green R, et al. Hypusine-containing protein eIF5A promotes translation elongation. Nature, 2009,459:118-121. [17] Hauber I, Bevec D, Heukeshoven J, et al. Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J Clin Invest,2005,115:76-85. [18] Kruse M, Rosorius O, Kratzer F, et al. Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA. J Exp Med, 2000,191:1581-1590. [19] Colvin SC, Maier B, Morris DL, et al. Deoxyhypusine synthase promotes differentiation and proliferation of T helper type 1 (Th1) cells in autoimmune diabetes. J Biol Chem, 2013,288:36226-36235. [20] Moore CC, Martin EN, Lee G, et al. Eukaryotic translation initiation factor 5A small interference RNA-liposome complexes reduce inflammation and increase survival in murine models of severe sepsis and acute lung injury. J Infect Dis,2008,198:1407-1414. [21] Templin AT, Maier B, Nishiki Y, et al. Deoxyhypusine synthase haploinsufficiency attenuates acute cytokine signaling. Cell Cycle,2011,10:1043-1049. [22] Hauber J. Revisiting an old acquaintance: role for eIF5A in diabetes. J Clin Invest,2010,120:1806-1808. [23] Maier B, Tersey SA, Mirmira RG. Hypusine: a new target for therapeutic intervention in diabetic inflammation. Discov Med,2010,10:18-23. |